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Introduction: Clinically unsuspected pulmonary embolism (PE)
can be detected in oncology patients undergoing computed tomog-
raphy (CT) imaging for reasons other than for PE diagnosis, but
there is little prospective data on its true prevalence, clinical impor-
tance, or on methods to improve detection.
Methods: In consecutive oncology patients undergoing CT imaging
of the chest for indications other than PE detection, CT pulmonary
angiography (CTPA) was systematically included as part of the
imaging protocol. Each imaging study was prospectively analyzed
for the presence of PE. A 6-month follow-up was performed.
Institutional review board approval was obtained.
Results: Four hundred seven oncology patients were included.
Indications for chest CT imaging included baseline staging (31%),
restaging after therapy (53%), routine surveillance (15%), or assess-
ment of extrathoracic disease (1%). Clinically unsuspected PE were
detected in 18 patients (4.4%). The prevalence of unsuspected PE
was 6.4% among inpatients and 3.4% among outpatients. PE was
more prevalent among patients with metastatic disease (7% versus
2%, p  0.007) and in patients who had received recent chemother-
apy (11% versus 3%, p  0.008). In 7 (39%) of the 18 patients with
clinically unsuspected PE, emboli were only identifiable on the
CTPA study and not on the routine chest CT study. The diagnosis of
PE led to immediate changes in patient management.
Conclusion: Clinically unsuspected PE is present in up to 4.4% of
oncology patients undergoing CT imaging for indications other than
PE diagnosis. Modifying standard CT imaging protocols to include
a CTPA examination optimizes their detection and leads to changes
in patient management.
Key Words: Pulmonary embolism, Oncology, CT pulmonary an-
giogram, MDCT.
(J Thorac Oncol. 2010;5: 798–803)
Acute pulmonary embolism (PE) is a common and oftenfatal disease, occurring in approximately 600,000 patients
annually in the United States and accounting for up to
150,000 deaths.1 Most cases of PE that eventually cause
fatality are clinically unsuspected and therefore go untreated
before death.2,3 Oncology patients have a fourfold higher risk
for developing pulmonary embolism than that of the general
population, increasing to sixfold if the patient is receiving
chemotherapy.4 In patients with cancer undergoing computed
tomography (CT) imaging for reasons other than for PE
detection, unsuspected PE has been found in up to 4% of
overall cases and in up to 9% of inpatients.5–7 Diagnosis of
unsuspected PE is important to prevent embolic recurrence
that is associated with substantial morbidity and mortality.8
CT pulmonary arteriography (CTPA) now represents
the diagnostic test of choice for the diagnosis of PE and is
widely available in most hospitals. The increasing availability
of newer generations of multidetector CT scanners (16- and
64-slice) with rapid rotation speeds has made it possible to
acquire thin-collimation images through large volumes of
imaged tissue, allowing high-quality reconstructions using
isometric voxels. In patients undergoing routine contrast-
enhanced CT imaging of the thorax for indications other than
PE detection, it is now possible to reconstruct the acquired
data to provide thin-slice images of the pulmonary arteries
equivalent to those in a CTPA study, provided that the
contrast delivery has been timed to optimize opacification of
the pulmonary arteries. By adjusting the imaging protocol
accordingly, high-quality images of the pulmonary arteries
can be acquired as part of a routine CT scan of the thorax. In
oncology patients undergoing routine staging or restaging CT
scans, we postulate that such an imaging protocol would
improve detection of incidental PE, which may help to
identify patients at risk for a subsequent major embolic event.
The objective of our study was to evaluate the diagnostic
usefulness of such a technique for the detection of clinically
unsuspected PE in oncology patients and to determine its
impact on patient management.
METHODS
This was a prospective longitudinal cohort study of
consecutive oncology patients undergoing multidetector CT
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imaging over a 10-month period from October 2007 to June
2008. The cohort comprised both inpatients and outpatients
undergoing CT imaging of the thorax, abdomen, and pelvis
for purposes other than PE detection. At our institution, we
employ a standard CT protocol for staging and restaging of
malignancies that comprises a contrast-enhanced CT of the
thorax, abdomen, and pelvis. We enrolled only patients who
would normally be imaged according to this protocol. Pa-
tients requiring different imaging protocols (e.g., dedicated
liver, pancreas, or renal CT protocols) were excluded. Patient
demographics (including age, sex, cancer diagnosis and
stage, current or recent treatment, prior history of thrombo-
embolic disease, indication for imaging, and the results of
recent blood tests) were recorded for each patient from the
patient’s medical records. For the purposes of the study,
tumor histology was categorized according to the general
histologic classification used by the American Joint Commit-
tee on Cancer.9 Cancer stage was broadly divided into those
with localized (no metastatic or systemic disease) and those
with evidence of systemic involvement (presence of metas-
tases or stage IV disease). Patients were considered to have
had recent chemotherapy if they had received treatment
within the 30 days before their CT examination. Details
regarding recent surgery and/or radiotherapy and current
anticoagulation status were also recorded.
Exclusion criteria included patients with any pretest
suspicion of pulmonary embolus; patients not undergoing
complete CT scanning of the thorax, abdomen, and pelvis;
patients with contraindications to IV contrast (allergy, renal
insufficiency, and pregnancy); and patients in whom adequate
IV access could not be obtained in the antecubital fossa.
Patients requiring different imaging protocols (e.g., dedicated
liver, pancreas, or renal CT protocols) were also excluded.
Ethics approval was obtained from the local institutional
review board.
Imaging Protocol
All scans were performed on a 64-slice multidetector
CT scanner (Siemens 64 Somatom Emotion, Erlangen, Ger-
many). The scanning protocol mandated a bolus intravenous
injection of 100 to 150 mL iodinated contrast at 4 to 5 mL/sec
via an antecubital vein along with a 20 mL saline flush; using
a bolus-tracking technique (region of interest over the main
pulmonary artery with a threshold of 100 Hounsfield units
[HU]), the scan was triggered at the point of maximal pul-
monary arterial enhancement (100 HU). A spiral CT scan of
the thorax from the lung apices to the adrenal glands was
acquired during this phase (kVp, 100–120; mAs adjusted
according to weight with tube modulation; pitch, 0.9; rotation
time, 0.5 seconds; collimation, 32  0.6 mm); delayed
imaging of the abdomen and pelvis was subsequently per-
formed during the phase of portal venous enhancement (40
seconds later). Images were reconstructed at 2 slice thick-
nesses: (a) for primary routine image interpretation, 5-mm
axial slices were reformatted of the entire dataset; (b) in
addition, for evaluation of the pulmonary arteries, contiguous
thin (1 or 1.5 mm) slices of the thorax were systematically
reformatted using soft tissue (window center, 40 HU; window
width, 400 HU; B20f filter) and lung (window center, 600
HU, window width, 1600 HU; B80f filter) algorithms and
window settings, respectively, providing an image subset of
the pulmonary arteries equivalent to a diagnostic CTPA
study. All images were archived electronically. We con-
structed into 5-mm slices as part of our routine protocol for
all CT of the thorax, abdomen, and pelvis examinations. One
millimeter slices of the thorax were performed for only those
patients included in the study because of picture archiving
and communication system (PACS) storage limitations.
Image Analysis
Each imaging study was prospectively evaluated on a
dedicated PACS workstation by a radiology resident and an
attending radiologist in consensus. Images (including both
the routine CT and the CTPA components) were analyzed by
scrolling through the dataset with the aid of a mouse; window
settings were adjusted to provide optimal visualization of the
pulmonary vasculature, which varied from patient to patient
according to the degree of contrast enhancement.
For the purposes of the study, the overall diagnostic
quality of the CTPA was evaluated based on the degree of
opacification of the pulmonary arteries and the presence or
absence of significant respiratory motion artifact. Studies that
were considered nondiagnostic for the detection of PE were
excluded from further analysis.
The presence and segmental location of incidental PE
were recorded for each patient. The presence of PE on the
CTPA images was defined according to established criteria
(pulmonary arterial luminal filling defect on at least two
consecutive axial images, associated with a crescent or ring
of contrast enhancement surrounding partial filling defects).10
Potential confounding artifacts were excluded (respiratory or
cardiogenic motion artifact, crossing unopacified pulmo-
nary veins, bronchial wall thickening, and peribronchial
lymph nodes) by careful analysis of anatomy and adjacent
lung parenchyma on both soft tissue and corresponding
lung windows.10,11
Routine evaluation of CT of the thorax, abdomen, and
pelvis with 5-mm slices was performed by the reporting
consultant covering the list as per normal practice. Within 24
hours, review of the thin images (1 mm) was performed first
by a radiology resident and then by a consultant radiologist
on a dedicated PACS workstation. If a filling defect was
identified on the thin slices, review of the thicker slice images
was performed to evaluate whether the filling defect could
have been diagnosed on the thicker slices and the same was
recorded.
All scans prospectively considered positive for PE were
reviewed and confirmed by two attending chest radiologists
with at least 7 years of experience in interpreting multidetec-
tor CTPA examinations (J.B., J.M.). Detected pulmonary
emboli were localized according to the modified Boyden
classification of segmental pulmonary arterial anatomy.12,13
Follow-up of Patients with PE
In cases of a positive PE diagnosis, details were re-
corded regarding the presence or absence of any of the
following: dyspnea, cough, hemoptysis, pleuritic chest pain,
and leg swelling. Any prior history of diagnosis and treatment
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of thromboembolic disease was documented. Details regard-
ing the subsequent management of these patients were also
recorded.
In addition, a later retrospective analysis was per-
formed of all patients at least 6 months after their study
protocol CTPA scan. This involved a review of all imaging
studies performed on these patients over the 6-month period
after their initial CTPA study (including repeat CT and CTPA
examinations, venous doppler ultrasound studies, and venti-
lation-perfusion [V/Q] scintigraphic studies), to document the
diagnosis of any new or recurrent venous thromboembolic
events.
For all those patients with PE on CT, the 6-month
follow-up included chart review and imaging review. All
follow-up imaging was examined separately by a radiology
resident and consultant radiologist along with the radiology
report. All patients had at least 6 months follow-up. All
patients had imaging in the subsequent 6-month period, and
the exact timing of this was at the discretion of the referring
clinician.
Statistical Analysis
Statistical analyses were performed using SPSS, ver-
sion 15, software (SPSS, Chicago, IL). The prevalence of
pulmonary emboli in each tumor group (according to histol-
ogy) was compared with the prevalence in the entire study
group by using the one-sided binomial test. The frequencies
of abnormal laboratory values in the patients with and in
those without pulmonary emboli were compared by using the
2 test. Logistic regression analysis was used to determine the
statistical association between PE and patient age, patient sex,
patient category (inpatient or outpatient), disease stage (me-
tastases or no metastases), chemotherapy status (currently
receiving or not), and cancer type (according to histology). A
p value of 0.05 was considered to indicate a statistically
significant difference.
RESULTS
A total of 408 patients were enrolled over a 10-month
period. Of the 408 CTPA studies acquired, 99% were of
either excellent (n  397) or satisfactory (n  10) image
quality; one study was considered unsatisfactory, and this
patient was excluded from further analysis. Three hundred
ninety-six studies were reconstructed at 1-mm collimation
and 11 studies were reconstructed at 1.5-mm collimation.
The remaining 407 study participants included 228
(56%) women and 179 (44%) men (mean age, 61 years; age
range, 16–89 years), comprising 140 (34%) inpatients and
267 (66%) outpatients (Table 1). Indications for CT com-
prised initial baseline staging (31%), evaluation of therapeu-
tic response after treatment (53%), routine surveillance while
off treatment (15%), or assessment of extrathoracic disease
(1%). Eighty-three (20%) patients had received chemother-
apy within 1 month before their CT. Two hundred eighteen
(54%) patients had localized disease at the time of scanning,
whereas 189 (46%) had systemic or metastatic disease.
Incidental unsuspected PE was diagnosed in a total of
18 patients (4.4%) (Table 2). At the time of scanning, only
one patient had dyspnea and cough, and one patient had
chest pain; all the other patients had no clinical symptoms
suggestive of PE. At the time of scanning patients, none of
these patients were suspected to have PE by their referring
clinicians.
The prevalence of unsuspected PE was 6.4% among
inpatients and 3.4% among outpatients (p  0.2). PE was
seen most commonly in patients with colorectal carcinoma (5
of 18), followed by transitional cell carcinoma of the bladder,
ovarian cancer, lymphoma, and esophageal cancer (2 of 18
each). The majority of patients with unsuspected PE had
systemic or metastatic disease (14 of 18, 78%).
The prevalence of unsuspected PE was significantly
higher among patients with metastatic malignancy (7%) than
in patients with more localized disease (2%) (p  0.007) and
among patients who had received recent chemotherapy (11%)
compared with patients who had not (3%) (p  0.005). No
other significant differences were seen between patients with
and without PE. On logistic regression analysis, only recent
chemotherapy was found to be a significant predictive factor
for the likelihood of incidental PE (p  0.008, 95% confi-
dence interval 1.05–12.44).
TABLE 1. Patient Demographics of Total Study Group
(n  407)
Characteristics n (%)
Male 179 (44)
Female 228 (56)
Age, yr (range) 60.7 (16–89)
Outpatient 267 (66)
Inpatient 140 (34)
Cancer types
Breast cancer 124 (31)
Colorectal cancer 55 (14)
Lymphoma 53 (13)
Gynaecological cancer 31 (8)
Renal cell cancer 23 (6)
Lung cancer 22 (5)
Transitional cell carcinoma of bladder 19 (5)
Melanoma 18 (4)
Testicular cancer 10 (2.5)
Oesophageal cancer 9 (2)
Carcinoma of unknown primary 8 (2)
Squamous cell carcinoma 7 (1.5)
Pancreatic cancer 6 (1)
Others 22 (5)
General cancer stage
Localized 218 (54)
Metastatic/stage IV 189 (46)
Chemotherapy
Recent (within 30 d) 83 (20)
None/remote 316 (78)
Unknown 8 (2)
Indication for scan—no./total no. (%)
Initial staging 127 (31)
Therapeutic response evaluation 215 (53)
Surveillance 59 (15)
Assessment of extrathoracic disease 7 (1)
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The most proximal arteries involved by PE comprised
the main pulmonary artery (4 patients, 22%), a lobar pulmo-
nary artery (5 patients, 28%), a segmental pulmonary artery
(6 patients, 33%), or a subsegmental pulmonary artery (3
patients, 17%). In 15 (83%) patients, emboli were present in
more than one pulmonary artery. Three (17%) patients had
isolated subsegmental filling defects. Pulmonary emboli lim-
ited to the segmental or subsegmental pulmonary arteries
were seen in 9 (50%) patients (Table 2, Figure 1).
In almost two-fifths (39%) of patients with PE, emboli
were confidently visualized on only the thin 1-mm reformat-
ted images and not on the thicker standard 5-mm slices. In the
remaining 61% of patients, the emboli were easily visualized
on both the thick and the thin slices.
Directed therapy with either systemic anticoagulation
or an inferior vena cava filter was instituted in 17 of the 18
patients with incidental PE. One patient with an incidental
isolated segmental PE was not treated with directed therapy
because of coexistent thrombocytopenia and a presumed
high risk of bleeding from anticoagulation therapy. This
patient subsequently represented 5 weeks later with symp-
tomatic multiple bilateral PE. There was no reported ther-
apy related complications on chart or imaging review in
the subsequent imaging period of those patients diagnosed
with unsuspected PE.
At 6-month follow-up review of the patient cohort,
there were no further thromboembolic events in the patients
who had been diagnosed with PE at their initial CTPA and
who had received anticoagulation. However, four other pa-
tients were diagnosed with clinically unsuspected PE on
subsequent routine tumor monitoring CT examinations; in
addition, six other patients presented with symptomatic PE,
and two other patients presented with symptomatic deep vein
thrombosis. None of these patients had evidence of pulmo-
nary emboli on their initial protocol CTPA. In total, there
were 22 (5.4%) oncology patients who were diagnosed with
unsuspected PE at some point over a period of 6 months.
DISCUSSION
Our findings show that, by incorporating a CTPA study
as a routine component of CT staging and restaging exami-
nations in oncology patients, clinically unsuspected PE can
be detected in up to 4.4% of patients, and that this changes
patient management.
Oncology patients are known at be at an increased risk
of venous thomboembolism that is up to four times that in the
general population,4,14 with a higher prevalence in inpatients
and in those receiving chemotherapy. In addition to the
hemostatic activation induced by the malignancy, oncology
patients are exposed to a wide range of other factors that put
them at increased risk for venous thromboembolic disease
including central line placement, immobilization, and the
thrombogenic effects of certain drugs.14–16 Early detection of
PE is important to reduce the morbidity and mortality asso-
ciated with recurrent pulmonary emboli.8
Patients with cancer undergo frequent CT imaging of
the chest for the purposes of diagnosis, staging, and surveil-
lance and for evaluation of intercurrent illness related to the
malignancy or its treatment. Previous studies have shown that
incidental, clinically unsuspected PE can be detected on these
CT examinations in 1.5 to 4% of patients5–7,17,18 and in up to
9% of inpatients with malignancy.5 Because of the high
volume of oncology patients undergoing CT imaging on a
routine basis, unsuspected PE is seen relatively frequently.
However, most of these earlier studies have been based on
analyses of CT scans performed on older generation technol-
ogy, which have not been optimized for depiction of the
pulmonary arterial vessels, and therefore, the true prevalence
of unsuspected PE has remained uncertain.7,19,20
CT pulmonary angiography (CTPA) is currently the
imaging modality of choice for the diagnosis of PE. It
involves acquiring thin-slice CT images of the pulmonary
TABLE 2. Patient Demographics of Patients with
Unsuspected PE (n  18)
Characteristic n (%)
Male 9 (50)
Female 9 (50)
Age, yr (range) 61.6 (32–84)
Outpatient 9 (50)
Inpatient 9 (50)
Indication for scan
Initial staging 5 (28)
Therapeutic response evaluation 10 (56)
Surveillance 2 (11)
Assessment of extra-thoracic disease 1 (5)
Cancer types
Colorectal cancer 5 (28)
Lymphoma 2 (11)
Oesophageal cancer 2 (11)
Ovarian cancer 2 (11)
Transitional cell carcinoma of bladder 2 (11)
Breast cancer 1 (5.6)
Carcinoma of unknown primary 1 (5.6)
Melanoma 1 (5.6)
Pancreatic cancer 1 (5.6)
Renal cell carcinoma
General cancer stage
Localized 4 (22)
Metastatic/stage IV 14 (78)
Chemotherapy
Recent (within 30 d) 9 (50)
None/remote 9 (50)
Coagulation status
Normal 12 (66)
Mildly elevated INR 1 (6)
Mild thrombocytopenia 2 (11)
Mild thrombocytosis 3 (17)
Most proximal divisional location of PE per patient
Main 4 (22)
Lobar 5 (28)
Segmental 6 (33)
Subsegmental 3 (17)
INR, international normalized ratio.
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arteries during the phase of maximal pulmonary arterial
contrast enhancement. The increasing availability of newer
generation (16-slice and 64-slice) multidetector CT scanners
has made it possible to acquire high-speed CT scans with thin
collimation as a matter of routine. Using automated bolus
tracking, fast acquisition speed, and thin collimation, modern
multidetector scanners can achieve isometric volume acqui-
sition that enables accurate depiction of peripheral subseg-
mental pulmonary arteries down to the level of sixth-order
vessels.21–23 Studies of CTPA have conclusively shown that
the use of thinner slice thickness is associated with increased
sensitivity for detection of PE in subsegmental vessels. Be-
cause up to 17% of patients with PE may only have isolated
subsegmental emboli,24 the use of thin-slice collimation is
important for optimal PE detection. In contrast, in CT exam-
inations performed for indications other than PE detection,
image slice thicknesses of 5 to 10 mm are generally used,
primarily for ease of interpretation and more efficient data
storage.
As far as we are aware, ours is the first prospective
study to systematically include an optimized CTPA protocol
using thin-slice (1 and 1.5 mm) image reconstructions as an
integral component of routine tumor monitoring CT scans in
patients with cancer. This was achieved by ensuring that
the delivery of IV contrast coincided with maximal pul-
monary arterial enhancement by using an automated “bo-
lus tracking” technique available on most multidetector CT
scanners and by obtaining reformatted thin-slice (1 mm)
axial images of the pulmonary arteries in all patients. It did
not involve any additional radiation exposure to the pa-
tient. Using this technique, we found an incidence of
clinically unsuspected PE in 4.4% patients (6.4% among
inpatients and 3.4% among outpatients), which is consis-
tent with that reported in other series.
Interestingly, in almost two-fifths (39%) of these pa-
tients, PE would not have been diagnosed without the thin-
slice CTPA images. These patients had emboli limited to
segmental and subsegmental vessels that, because of partial
volume averaging effects, were partially obscured by high-
attenuation contrast on thicker-slice images. Therefore, small
segmental and subsegmental pulmonary emboli may be over-
looked if pulmonary arterial analysis is limited to thick-slice
images, even when the CT technique is optimized to obtain
maximal pulmonary arterial contrast enhancement. The use
of thin-slice reformats effectively eliminates partial volume
averaging effect and improves diagnostic confidence.
Currently, there is no evidence to support the treatment
of incidental PE. However, it still remains uncertain that not
treating incidental PE is not associated with a risk of future
events. It remains the responsibility of the interpreting radi-
ologist to report if a PE is identified, and the onus is then of
the clinician to determine optimal treatment on the clinician
on whether or not to treat an unsuspected pulmonary embo-
lus.25 Small peripheral emboli, while not immediately life
threatening, may cause pulmonary infarction resulting in
pleuritic chest pain and hemoptysis; they may also herald
larger and life-threatening emboli. Untreated recurrent PE
can lead to chronic pulmonary thromboembolic disease and
pulmonary arterial hypertension. In all but one of the patients
in our study diagnosed with incidental PE, anticoagulation
FIGURE 1. Radiographic images. A–C, Axial computed tomography (CT) images reconstructed at 1-mm thickness shows def-
inite filling defects in two segmental pulmonary arteries in the right lower lobe pulmonary artery, which extended over con-
secutive axial images and met the diagnostic criteria for a diagnosis of pulmonary emboli (PE). D–F, Axial consecutive images
of a routine restaging CT thorax at 5-mm thickness (same scan, same level, same window parameters as in A–C above) shows
a subtle nonspecific filling defect in a segmental right lower lobe pulmonary artery, seen only on one slice (B), which did not
meet diagnostic criteria for PE. The patient was completely asymptomatic at the time of scanning.
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therapy was instituted immediately, and these patients had no
further thromboembolic events over the subsequent 6 months.
The one patient who did not receive directed therapy had an
isolated segmental PE; subsequently, 5 weeks later, he pre-
sented with multiple bilateral lobar and segmental pulmonary
emboli, which were acutely symptomatic.
Modifying routine staging and surveillance CT proto-
cols to include diagnostic quality CTPA examinations is
easily achievable, but it poses logistical challenges in terms
of data storage and image interpretation times. The acquisi-
tion of the additional CTPA study produces approximately an
extra 200 images that need to be archived, effectively dou-
bling the overall size of the entire CT study (220 MB versus
100 MB) and thereby increasing data storage costs. Interpre-
tation of a CTPA study involves not only an analysis of the
pulmonary arteries but also of the lung parenchyma for subtle
abnormalities (such as small pulmonary nodules) that may
have been missed on the routine thick-slice images, prolong-
ing the reading time. This cost—both directly fiscal and
indirectly fiscal in terms of image interpretation throughput—
must be set against the gains in terms of improved PE
detection and characterization of parenchymal abnormalities.
The results of the current and of prior studies empha-
size the need to analyze the pulmonary arteries in all oncol-
ogy patients undergoing CT imaging of the chest, particularly
in inpatients, patients with advanced systemic or metastatic
malignancy, and those having received recent chemotherapy.
The detection of incidental PE will lead to significant changes
in patient management; conversely, overlooking incidental
PE may have adverse effects on patient outcomes. The
current study describes a practical method for optimizing PE
detection in oncology patients.
CONCLUSION
Our findings show that clinically unsuspected PE is
present in up to 4.4% of oncology patients undergoing routine
staging and surveillance CT scans. Modifying standard CT
imaging protocols to include a CTPA examination optimizes
their detection and leads to changes in patient management.
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